HIGHLIGHTS
- who: Toni Herta and collaborators from the Division of Hepatology, Department of Medicine II, Leipzig University Medical Center have published the article: Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection, in the Journal: Pathogens 2022, 11, 517. of 25/04/2022
- what: The authors report the long-term treatment response in three patients that were treated for >48 weeks.
- future: An extension of treatment to 48 weeks and the combination of BLV with PEG-IFNu03b1 in the MYR203 study increased . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.